The use of primary and secondary doxazosin XL (8 mg) in the treatment of benign prostate hyperplasia: Is there a new approach in the event of alpha-blocker failure?
Abstract Objective: Lower urinary tract symptoms (LUTS), which are related to benign prostate hyperplasia (BPH), are the most commonly encountered diseases in urological practice. In our study, we compared responses to doxazosin mesylate extended release tablets (doxazosin XL) (8 mg) treatment betw...
I tiakina i:
| Ngā kaituhi matua: | , , , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
Turkish Association of Urology
2019-07-01
|
| Rangatū: | Urology Research and Practice |
| Ngā marau: | |
| Urunga tuihono: | http://urologyresearchandpractice.org/index.php/pub/article/view/2764 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|